ScoreWhy is Moderna, Inc. ?
1
Flat results in Jun 25
- NET SALES(Q) At USD 142 MM has Fallen at -82.12%
- NET PROFIT(9M) At USD -2,916 MM has Grown at -30.35%
- RAW MATERIAL COST(Y) Grown by 172.78% (YoY)
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -43.31%, its profits have risen by 44.1%
3
High Institutional Holdings at 80.3%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 2.16% over the previous quarter.
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -43.31% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Moderna, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Moderna, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Moderna, Inc.
-40.14%
-1.25
66.85%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
96.21%
EBIT Growth (5y)
-234.26%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
0.47
Tax Ratio
1.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.30%
ROCE (avg)
68.02%
ROE (avg)
25.33%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.05
EV to EBIT
-1.26
EV to EBITDA
-1.33
EV to Capital Employed
1.13
EV to Sales
1.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-90.22%
ROE (Latest)
-33.35%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend2What is working for the Company
NET PROFIT(HY)
Higher at USD -1,796 MM
-14What is not working for the Company
NET SALES(Q)
At USD 142 MM has Fallen at -82.12%
NET PROFIT(9M)
At USD -2,916 MM has Grown at -30.35%
RAW MATERIAL COST(Y)
Grown by 172.78% (YoY
Here's what is working for Moderna, Inc.
Net Profit
Higher at USD -1,796 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Depreciation
At USD 57 MM has Grown at 46.15%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (USD MM)
Here's what is not working for Moderna, Inc.
Net Sales
At USD 142 MM has Fallen at -82.12%
over average net sales of the previous four periods of USD 794.25 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Raw Material Cost
Grown by 172.78% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
